Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR (e.g. Named Patient Program (NPP)). For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and

continue to meet eligibility will transition to an extension phase of the study and the base study will be closed.

The extension phase will begin as soon as the protocol amendment is implemented.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• Advanced cutaneous T-cell lymphoma on or following two systemic therapies

• Female participants must have a negative serum pregnancy test within 3 days of the first dose of vorinostat

• Female participants must have finished menopause, or are surgically sterilized, or agree to use 2 adequate barrier methods of contraception

• Male participants must agree to use 2 adequate barrier methods of contraception

• To be treated on extension phase of study participant must have been treated on the base study for Protocol 042

Exclusion Criteria:

• Currently receiving any potential histone deacetylase (HDAC) inhibitor (e.g. valproic acid)

• Currently receiving any other systemic therapy for CTCL. Corticosteroids that are similar in strength to 20 mg of prednisone daily are permitted

• Pregnant or lactating

• Known allergy to any component of the study drug

• Eligible for any other study of vorinostat in CTCL patients